LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 7 of total 7

Search options

  1. Article ; Online: A 71-year-old woman with an unusual cause for pleural effusions.

    Rafii, Rokhsara / Leslie, Kevin / Heo, Joline / Chan, Andrew

    Chest

    2011  Volume 139, Issue 5, Page(s) 1237–1241

    MeSH term(s) Aged ; Amyloidosis/complications ; Amyloidosis/diagnosis ; Female ; Humans ; Pleural Diseases/complications ; Pleural Diseases/diagnosis ; Pleural Effusion/etiology
    Language English
    Publishing date 2011-05
    Publishing country United States
    Document type Case Reports ; Journal Article ; Research Support, N.I.H., Extramural ; Research Support, U.S. Gov't, Non-P.H.S.
    ZDB-ID 1032552-9
    ISSN 1931-3543 ; 0012-3692
    ISSN (online) 1931-3543
    ISSN 0012-3692
    DOI 10.1378/chest.10-1375
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui III Zs.45: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 349: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Smoking and smoking cessation in pregnancy.

    Murin, Susan / Rafii, Rokhsara / Bilello, Kathryn

    Clinics in chest medicine

    2011  Volume 32, Issue 1, Page(s) 75–91

    Abstract: Smoking during pregnancy is among the leading preventable causes of adverse maternal and fetal outcomes. Smoking prevalence among young women is the primary determinant of smoking prevalence during pregnancy. Smoking among women of childbearing age is ... ...

    Abstract Smoking during pregnancy is among the leading preventable causes of adverse maternal and fetal outcomes. Smoking prevalence among young women is the primary determinant of smoking prevalence during pregnancy. Smoking among women of childbearing age is associated with reduced fertility, increased complications of pregnancy, and a variety of adverse fetal outcomes. There is increasing evidence of lasting adverse effects on offspring. Guidelines for smoking cessation during pregnancy have been developed. This article reviews the epidemiology of smoking during pregnancy, the adverse effects of smoking on the mother, fetus, and offspring, and recommended approaches to smoking cessation for pregnant women.
    MeSH term(s) Attention Deficit Disorder with Hyperactivity/epidemiology ; Attention Deficit Disorder with Hyperactivity/etiology ; Cognition Disorders/epidemiology ; Cognition Disorders/etiology ; Female ; Humans ; Infant, Low Birth Weight ; Infant, Newborn ; Infertility, Female/epidemiology ; Infertility, Female/etiology ; Maternal-Fetal Exchange ; Nervous System Physiological Phenomena/drug effects ; Nicotine/adverse effects ; Overweight/epidemiology ; Overweight/etiology ; Pregnancy ; Pregnancy Complications/epidemiology ; Pregnancy Complications/etiology ; Pregnancy Outcome ; Prenatal Exposure Delayed Effects/epidemiology ; Prenatal Exposure Delayed Effects/etiology ; Respiratory Tract Diseases/epidemiology ; Respiratory Tract Diseases/etiology ; Risk Factors ; Smoking/adverse effects ; Smoking/epidemiology ; Smoking/trends ; Smoking Cessation/methods ; Smoking Cessation/psychology ; Smoking Cessation/statistics & numerical data ; Sudden Infant Death/epidemiology ; Sudden Infant Death/etiology ; United States/epidemiology
    Chemical Substances Nicotine (6M3C89ZY6R)
    Language English
    Publishing date 2011-03
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 447455-7
    ISSN 1557-8216 ; 0272-5231
    ISSN (online) 1557-8216
    ISSN 0272-5231
    DOI 10.1016/j.ccm.2010.11.004
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Se 805: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Update on Pharmaceutical and Minimally Invasive Management Strategies for Chronic Obstructive Pulmonary Disease

    Andrew L. Chan / Rokhsara Rafii / Samuel Louie / Timothy E. Albertson

    Pulmonary Medicine, Vol

    2011  Volume 2011

    Keywords Internal medicine ; RC31-1245 ; Medicine ; R ; DOAJ:Internal medicine ; DOAJ:Medicine (General) ; DOAJ:Health Sciences ; Diseases of the respiratory system ; RC705-779
    Language English
    Publishing date 2011-01-01T00:00:00Z
    Publisher Hindawi Publishing Corporation
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  4. Article: A review of current and novel therapies for idiopathic pulmonary fibrosis.

    Rafii, Rokhsara / Juarez, Maya M / Albertson, Timothy E / Chan, Andrew L

    Journal of thoracic disease

    2012  Volume 5, Issue 1, Page(s) 48–73

    Abstract: Idiopathic pulmonary fibrosis (IPF) is a progressively fibrotic interstitial lung disease that is associated with a median survival of 2-3 years from initial diagnosis. To date, there is no treatment approved for IPF in the United States, and only one ... ...

    Abstract Idiopathic pulmonary fibrosis (IPF) is a progressively fibrotic interstitial lung disease that is associated with a median survival of 2-3 years from initial diagnosis. To date, there is no treatment approved for IPF in the United States, and only one pharmacological agent has been approved outside of the United States. Nevertheless, research over the past 10 years has provided us with a wealth of information on its histopathology, diagnostic work-up, and a greater understanding of its pathophysiology. Specifically, IPF is no longer thought to be a predominantly pro-inflammatory disorder. Rather, the fibrosis in IPF is increasingly understood to be the result of a fibroproliferative and aberrant wound healing cascade. The development of therapeutic targets has shifted in accord with this paradigm change. This review highlights the current understanding of IPF, and the recent as well as novel therapeutics being explored in clinical trials for the treatment of this devastating disease.
    Language English
    Publishing date 2012-01-01
    Publishing country China
    Document type Journal Article
    ZDB-ID 2573571-8
    ISSN 2077-6624 ; 2072-1439
    ISSN (online) 2077-6624
    ISSN 2072-1439
    DOI 10.3978/j.issn.2072-1439.2012.12.07
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Therapeutic update in idiopathic pulmonary fibrosis.

    Chan, Andrew L / Rafii, Rokhsara / Louie, Samuel / Albertson, Timothy E

    Clinical reviews in allergy & immunology

    2011  Volume 44, Issue 1, Page(s) 65–74

    Abstract: Idiopathic pulmonary fibrosis (IPF) is a disease of the elderly with a mean age at presentation of 66 years. It is the most common type of idiopathic lung fibrosis, and the most lethal, with a median survival of 3 to 5 years after diagnosis. ... ...

    Abstract Idiopathic pulmonary fibrosis (IPF) is a disease of the elderly with a mean age at presentation of 66 years. It is the most common type of idiopathic lung fibrosis, and the most lethal, with a median survival of 3 to 5 years after diagnosis. Abnormalities in fibroblast and humoral response mechanisms may play a role in the pathogenesis of fibrosis in IPF. Clinical trials suggest that pirfenidone, an oral antifibrotic agent, N-acetylcysteine, an antioxidant and perhaps anticoagulation, may have some beneficial effect; however, large-scale studies are necessary for confirmation. Immunosuppression with corticosteroids likely does not confer benefit. Lung transplantation has been shown to improve survival in selected IPF patients. Comorbidities accompanying IPF include gastroesophageal reflux, sleep disturbance, pulmonary arterial hypertension, and coronary artery disease amongst others, and ought to be promptly recognized and managed appropriately. While the US Food and Drug Administration has not currently approved any treatments for IPF, patients with IPF should continue to be strongly encouraged to enroll in ongoing clinical trials for this devastating disease.
    MeSH term(s) Aged ; Clinical Trials as Topic ; Comorbidity ; Female ; Humans ; Idiopathic Pulmonary Fibrosis/diagnosis ; Idiopathic Pulmonary Fibrosis/therapy ; Lung Transplantation
    Language English
    Publishing date 2011-01-11
    Publishing country United States
    Document type Case Reports ; Journal Article ; Review
    ZDB-ID 1239045-8
    ISSN 1559-0267 ; 1080-0549
    ISSN (online) 1559-0267
    ISSN 1080-0549
    DOI 10.1007/s12016-010-8244-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1844: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Update on pharmaceutical and minimally invasive management strategies for chronic obstructive pulmonary disease.

    Rafii, Rokhsara / Albertson, Timothy E / Louie, Samuel / Chan, Andrew L

    Pulmonary medicine

    2011  Volume 2011, Page(s) 257496

    Abstract: Chronic obstructive pulmonary disease (COPD) is a debilitating pulmonary disorder with systemic effects, and it is the fourth leading cause of death in the United States. COPD patients not only develop respiratory limitations, but can also demonstrate ... ...

    Abstract Chronic obstructive pulmonary disease (COPD) is a debilitating pulmonary disorder with systemic effects, and it is the fourth leading cause of death in the United States. COPD patients not only develop respiratory limitations, but can also demonstrate systemic wasting, features of depression, and can succumb to social isolation. Smoking cessation is crucial, and pharmacotherapy with bronchodilators is helpful in symptom management. Inhaled corticosteroids may be beneficial in some patients. In addition, pulmonary rehabilitation and palliative care are important components under the right clinical circumstance. This review highlights current guidelines and management strategies for COPD and emphasizes novel pharmacotherapy and minimally invasive (nonsurgical) lung-volume reduction interventions that may prove to be of significant benefit in the future.
    Language English
    Publishing date 2011-04-20
    Publishing country Egypt
    Document type Journal Article
    ZDB-ID 2603580-7
    ISSN 2090-1844 ; 2090-1836
    ISSN (online) 2090-1844
    ISSN 2090-1836
    DOI 10.1155/2011/257496
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article: Hemodialysis complications of hydroxocobalamin: a case report.

    Sutter, Mark / Tereshchenko, Nadia / Rafii, Rokhsara / Daubert, G Patrick

    Journal of medical toxicology : official journal of the American College of Medical Toxicology

    2010  Volume 6, Issue 2, Page(s) 165–167

    Abstract: Hydroxocobalamin is a new antidote approved by the FDA for the treatment of cyanide poisoning. Our report describes a patient with cyanide poisoning who survived after treatment with hydroxocobalamin and complications we encountered with hemodialysis. A ... ...

    Abstract Hydroxocobalamin is a new antidote approved by the FDA for the treatment of cyanide poisoning. Our report describes a patient with cyanide poisoning who survived after treatment with hydroxocobalamin and complications we encountered with hemodialysis. A 34-year-old female presented to the emergency department after a syncopal event and seizures. Her systolic blood pressure was 75 mmHg, her QRS complex progressively widened, and pulses were lost. She was intubated and resuscitated with fluids, sodium bicarbonate for her QRS widening and vasopressors. Venous blood gas demonstrated a pH of 6.36 with an O₂ saturation of 99%. Due to the acidemia with a normal pulse oximetry, simultaneous venous and arterial blood gases were obtained. Venous gas demonstrated a pH of 6.80 with a PO₂ of 222 mmHg, an O₂ saturation of 99%. The arterial blood gas showed a pH of 6.82, a PO₂ 518 mmHg, an O₂ saturation of 100%. Cyanide was suspected and hydroxocobalamin and sodium thiosulfate were given. Within 40 min of hydroxocobalamin administration, vasopressors were discontinued. Initially, nephrology attempted dialysis for metabolic acidosis; however, the dialysis machine repeatedly shut down due to a "blood leak". This was an unforeseen effect attributed to hydroxocobalamin. Cyanide level, drawn 20 min after the antidote was completed, was elevated at 22 mcg/dL. Her urinary thiocyanate level could not be analyzed due to an "interfering substance". Hydroxocobalamin is an effective antidote. However, clinicians must be aware of its effects on hemodialysis machines which could delay the initiation of this important treatment modality in the severely acidemic patient.
    MeSH term(s) Acidosis/chemically induced ; Acidosis/therapy ; Adult ; Antidotes/adverse effects ; Antidotes/therapeutic use ; Bipolar Disorder/complications ; Cyanides/poisoning ; Female ; Humans ; Hydroxocobalamin/adverse effects ; Hydroxocobalamin/therapeutic use ; Renal Dialysis ; Seizures/chemically induced ; Syncope/chemically induced ; Thiosulfates/therapeutic use
    Chemical Substances Antidotes ; Cyanides ; Thiosulfates ; sodium thiosulfate (HX1032V43M) ; Hydroxocobalamin (Q40X8H422O)
    Language English
    Publishing date 2010-03-30
    Publishing country United States
    Document type Case Reports ; Journal Article
    ZDB-ID 2435016-3
    ISSN 1937-6995 ; 1556-9039
    ISSN (online) 1937-6995
    ISSN 1556-9039
    DOI 10.1007/s13181-010-0067-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6682: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top